These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26098833)

  • 1. The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
    Lian F; Tian J; Chen X; Li Z; Piao C; Guo J; Ma L; Zhao L; Xia C; Wang CZ; Yuan CS; Tong X
    PLoS One; 2015; 10(6):e0130550. PubMed ID: 26098833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Chinese herbal medicine Jinlida in type 2 diabetes patients based on stratification: Results of subgroup analysis from a 12-week trial.
    Tian J; Lian F; Yang L; Tong X
    J Diabetes; 2018 Feb; 10(2):112-120. PubMed ID: 28418191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effectiveness of Traditional Chinese Medicine Jinlida Granules on Glycemic Variability in Newly Diagnosed Type 2 Diabetes: A Double-Blinded, Randomized Trial.
    Pan J; Xu Y; Chen S; Tu Y; Mo Y; Gao F; Zhou J; Hu C; Jia W
    J Diabetes Res; 2021; 2021():6303063. PubMed ID: 34660811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Gao L; Cheng Z; Su B; Su X; Song W; Guo Y; Liao L; Chen X; Li J; Tan X; Xu F; Pang S; Wang K; Ye J; Wang Y; Chen L; Sun J; Ji L
    Diabetes Obes Metab; 2023 Mar; 25(3):785-795. PubMed ID: 36433709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A; Lipetz R; Wu J; Schwartz S
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison study of metformin only therapy and metformin combined with Chinese medicine jianyutangkang therapy in patients with type 2 diabetes: A randomized placebo-controlled double-blind study.
    Hu Y; Zhou X; Liu P; Wang B; Duan DM; Guo DH
    Complement Ther Med; 2016 Feb; 24():13-8. PubMed ID: 26860796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
    BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial.
    Tong XL; Wu ST; Lian FM; Zhao M; Zhou SP; Chen XY; Yu B; Zhen Z; Qi LW; Li P; Wang CZ; Sun H; Yuan CS
    Diabetes Obes Metab; 2013 May; 15(5):448-54. PubMed ID: 23231379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.
    Ji H; Zhao X; Chen X; Fang H; Gao H; Wei G; Zhang M; Kuang H; Yang B; Cai X; Su Y; Piao C; Zhao S; Li L; Sun W; Xu T; Xu Q; Fan Y; Ye J; Yao C; Shang M; Song G; Chen L; Zheng Q; Xiao X; Yan L; Lian F; Tong X; Jia Z;
    JAMA Intern Med; 2024 Jul; 184(7):727-735. PubMed ID: 38829648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial.
    Huang YH; Chen ST; Liu FH; Hsieh SH; Lin CH; Liou MJ; Wang CC; Huang CH; Liu GH; Lin JR; Yang LY; Hsu TY; Lee MC; Huang CT; Wu YH
    PLoS One; 2019; 14(8):e0221199. PubMed ID: 31415655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of traditional Chinese medicine Jinlida granules as an add-on therapy for type 2 diabetes: A system review and meta-analysis of randomized controlled trials.
    Lian F; Jin D; Bao Q; Zhao Y; Tong X
    J Diabetes; 2019 Jul; 11(7):540-551. PubMed ID: 30430757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
    Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.